Clinical Trial Update: Efficacy Study With 500 mg QD of TRO19622 vs Placebo in Patients With Painful Peripheral Diabetic Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TRO19622 500 mg once daily vs placebo for painful peripheral diabetic neuropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• TRO19622

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetic Neuropathy | Phase 2 | Status: COMPLETED